Patient recruitment for Krillase€ study completed

Patient recruitment for Krillase® study completed In July, BioPhausia completed recruitment of a total of 179 patients for the Krillase® phase III clinical study. This study compares the effectiveness of Krillase® with three of the leading current treatments for the debridement of chronic wounds covered by pus and other dead tissue. Previous interim analysis, based on assumptions about the effects of Krillase®, indicates that the number of patients now recruited is sufficient. The study is being carried out at the University clinics in Freiburg, Amsterdam and Cardiff. "I am pleased to report that the final patient has now joined the study," says BioPhausia's President, Stellan Lind. "Treatment of the final patients will take four to six weeks. Processing the results is then expected to take another four weeks." Uppsala, August 4, 1998 Based on its contact network and know-how, primarily in connective-tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The project portfolio includes RescueFlow®, a resuscitation solution (registration phase), Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. Please contact the President, Stellan Lind, for further information. Tel. +46-18-34 99 00